Today's Low
₹ 565.20
Today's High
₹ 585.70
52 Weeks Low
₹ 145.15
52 Weeks High
₹ 293.80
Lower
₹ 529.95
Upper
₹ 585.70
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, Europe, and internationally. The company offers generic products comprising injectables, such as cephalosporins and non-cephalosporins; molecules; and value-added generics. Its biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. The company also provides contract manufacturing services for sterile injectables, lyophilisation, and other dosage forms; and research services. It develops various molecules primarily in the area of infectious disease, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company was incorporated in 1999 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2008 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1,914.0 | 2,445.0 | 2,425.0 | 2,400.5 | 2,814.7 | 3,379.6 | 4,535.3 | 3,951.9 | 3,521.6 | 3,355.9 | 3,326.9 | 2,481.5 | 3,118.7 |
Total Non-Current Assets | 4,867.0 | 5,081.0 | 4,951.0 | 5,319.7 | 4,756.4 | 4,598.9 | 4,313.6 | 4,023.9 | 3,983.2 | 3,266.1 | 2,671.5 | 3,772.3 | 3,722.9 |
Total Assets | 7,075.0 | 7,670.0 | 7,376.0 | 7,749.5 | 7,571.0 | 7,978.5 | 8,848.8 | 7,975.8 | 7,504.7 | 6,622.0 | 5,998.5 | 6,253.8 | 6,841.6 |
Total Current Liabilities | 3,435.0 | 3,207.0 | 3,121.0 | 3,497.2 | 2,863.7 | 2,691.7 | 1,978.8 | 1,841.9 | 1,773.0 | 1,743.2 | 1,773.5 | 1,890.9 | 1,630.3 |
Total Non-Current Liabilities | -22.0 | 261.0 | 496.0 | 1,194.9 | 1,702.8 | 2,088.9 | 3,151.4 | 1,893.5 | 1,872.5 | 1,161.2 | 1,520.8 | 2,891.9 | 4,193.6 |
Shareholder's Funds | 3,354.0 | 3,849.0 | 3,376.0 | 2,671.7 | 2,674.8 | 2,852.2 | 3,336.7 | 3,775.1 | 3,715.4 | 3,581.5 | 2,704.2 | 1,471.0 | 1,017.7 |
Total Liabilities | 7,075.0 | 7,670.0 | 7,376.0 | 7,749.5 | 7,571.0 | 7,978.5 | 8,848.8 | 7,975.8 | 7,504.7 | 6,622.0 | 5,998.5 | 6,253.8 | 6,841.6 |
The Industry Debt to Equity Ratio stands at 0.22, vs the Debt to Equity Ratio of 1.22, which results in a Negative aspect.
The Industry Quick Ratio stands at 1.60, vs the Quick Ratio of 0.48, which results in a Negative aspect.
The Industry Current Ratio stands at 2.30, vs the Current Ratio of 0.69, which results in a Negative aspect.
The Industry Price to BV stands at 6.12, vs the Price to BV of 2.64, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2008 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 2,651.0 | 3,230.0 | 2,708.0 | 2,844.0 | 3,565.8 | 3,936.9 | 4,014.6 | 4,453.2 | 4,481.5 | 4,830.4 | 5,609.4 | 4,350.5 | 3,589.8 |
Total Expenditure | 2,550.0 | 2,932.0 | 2,771.0 | 2,746.2 | 3,604.3 | 3,992.3 | 4,001.8 | 3,959.0 | 3,772.1 | 3,850.5 | 3,549.7 | 2,996.8 | 2,933.8 |
Operating Profit(Excl OI) | 223.0 | 318.0 | 69.0 | 157.8 | -17.5 | 122.1 | 127.1 | 560.3 | 776.0 | 1,064.1 | 2,113.7 | 1,379.1 | 702.2 |
Add: Other Income | 122.0 | 20.0 | 132.0 | 60.1 | 21.0 | 177.5 | 114.3 | 66.1 | 66.6 | 84.3 | 54.0 | 25.3 | 46.1 |
Operating Profit | 223.0 | 318.0 | 69.0 | 157.8 | -17.5 | 122.1 | 127.1 | 560.3 | 776.0 | 1,064.1 | 2,113.7 | 1,379.1 | 702.2 |
Less: Interest | 302.0 | 299.0 | 249.0 | 275.7 | 265.1 | 255.5 | 225.3 | 129.0 | 55.2 | 83.4 | 215.4 | 269.0 | 259.1 |
PBDT | -79.0 | 19.0 | -180.0 | -117.9 | -282.6 | -133.4 | -98.2 | 431.4 | 720.7 | 980.8 | 1,898.3 | 1,110.0 | 443.1 |
Less: Depreciation Amortization | 251.0 | 247.0 | 246.0 | 224.1 | 164.0 | 149.5 | 148.9 | 141.9 | 145.4 | 139.9 | 122.1 | 115.1 | 113.1 |
PBT & Exceptional Items | -330.0 | -228.0 | -426.0 | -342.0 | -446.6 | -283.0 | -247.2 | 289.5 | 575.3 | 840.8 | 1,776.2 | 995.0 | 330.0 |
Less: Exceptional Income Expenses | -294.0 | -183.0 | -142.0 | 0.0 | 0.0 | -358.2 | 0.0 | 0.0 | 0.0 | 49.8 | 61.5 | -473.8 | -581.0 |
Profit Before Tax | -624.0 | -411.0 | -568.0 | -342.0 | -446.6 | -641.2 | -247.2 | 289.5 | 575.3 | 890.7 | 1,837.7 | 521.2 | -251.0 |
Less: Taxation | -3.0 | -132.0 | -271.0 | -204.1 | -134.8 | 25.7 | -21.1 | 37.9 | 162.7 | 47.9 | 258.2 | 221.7 | -91.6 |
Profit After Tax | -621.0 | -279.0 | -297.0 | -138.0 | -311.8 | -666.9 | -226.0 | 251.6 | 412.7 | 842.8 | 1,579.5 | 299.5 | -159.3 |
Earnings Per Share | -38.8 | -16.9 | 57.5 | -5.8 | -16.2 | -50.7 | -16.3 | 20.9 | 33.9 | 58.9 | 132.8 | 25.3 | -1.2 |
The Industry PAT Growth stands at 32.49, vs the PAT Growth of 55.76, which results in a Positive aspect.
The Industry Dividend Yield stands at 0.59, vs the Dividend Yield of 0.00, which results in a Negative aspect.
The Industry PAT Margin stands at 9.68, vs the PAT Margin of -4.85, which results in a Negative aspect.
The Industry PE Ratio stands at 42.11, vs the PE Ratio of 0.00, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2008 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | -624.0 | -411.0 | 916.0 | -196.7 | -300.3 | -641.2 | -247.2 | 289.5 | 575.3 | 890.7 | 1,860.2 | 576.7 | 104.4 | -985.6 | -251.0 |
Tax Paid | -11.0 | -97.0 | -117.0 | -17.2 | -41.2 | -17.5 | -28.0 | -83.9 | -161.4 | -135.9 | -334.1 | -20.5 | -3.0 | -46.9 | -31.2 |
Adjustment | 635.0 | 554.0 | -943.0 | 483.2 | 444.5 | 448.8 | 303.0 | 262.0 | 285.6 | 133.5 | 273.3 | 917.6 | 495.4 | 1,078.0 | 976.3 |
Changes In Working Capital | -624.0 | -411.0 | 916.0 | -196.7 | -300.3 | -641.2 | -247.2 | 289.5 | 575.3 | 890.7 | 1,860.2 | 576.7 | 104.4 | -985.6 | -251.0 |
Cash Flow after changes in Working Capital | 164.0 | 510.0 | -170.0 | 666.1 | 224.5 | 86.0 | -241.5 | 155.5 | 516.4 | 1,612.2 | 1,866.5 | 1,364.4 | 644.8 | -151.8 | 155.7 |
Cash Flow from Operating Activities | 153.0 | 413.0 | -287.0 | 649.0 | 183.3 | 68.4 | -269.5 | 71.6 | 355.0 | 1,476.3 | 1,532.4 | 1,343.8 | 641.8 | -198.7 | 124.5 |
Cash Flow from Investing Activities | -125.0 | -201.0 | 1,470.0 | -155.5 | 94.6 | 630.2 | -686.6 | -818.2 | -206.6 | -851.6 | 1,085.4 | -305.5 | -276.6 | 704.3 | -1,198.1 |
Cash Flow from Financing Activities | -315.0 | -71.0 | -1,171.0 | -679.6 | -776.5 | -769.5 | 1,254.5 | 254.3 | -75.7 | -601.3 | -2,245.8 | -826.6 | -373.0 | -395.7 | 1,039.9 |
Net Cash Inflow / Outflow | -287.0 | 141.0 | 12.0 | -186.2 | -498.6 | -70.8 | 298.4 | -492.3 | 72.7 | 23.4 | 372.0 | 211.8 | -7.8 | 110.0 | -33.7 |
Opening Cash & Cash Equivalents | 370.0 | 232.0 | 219.0 | 397.3 | 897.2 | 963.6 | 663.0 | 1,158.7 | 1,101.7 | 1,050.0 | 689.7 | 470.1 | 314.1 | 212.2 | 377.3 |
Closing Cash & Cash Equivalent | 90.0 | 370.0 | 232.0 | 219.3 | 397.3 | 897.2 | 963.6 | 664.6 | 1,158.7 | 1,101.7 | 1,050.0 | 689.7 | 470.1 | 314.1 | 212.2 |
The Industry PCF RATIO stands at 24.36, vs the PCF RATIO of 2.72, which results in a Negative aspect.
The Industry PFCF Ratio stands at 25.03, vs the PFCF Ratio of 5.98, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 7,010.0 | 7,530.0 | 6,440.0 | 6,780.0 | 6,990.0 | 6,790.0 | 5,950.0 | 6,550.0 | 8,538.9 | 8,620.0 | 8,595.5 | 6,319.6 | 7,640.2 | 7,140.5 | 5,982.7 | 6,869.3 |
Total Income | 7,090.0 | 7,770.0 | 6,580.0 | 7,100.0 | 7,010.0 | 7,360.0 | 6,520.0 | 6,690.0 | 8,559.4 | 8,672.0 | 8,744.5 | 6,537.0 | 8,671.5 | 7,302.9 | 6,062.2 | 7,081.0 |
Total Expenditure | 6,640.0 | 6,810.0 | 6,280.0 | 6,750.0 | 6,540.0 | 6,360.0 | 6,110.0 | 6,880.0 | 7,424.4 | 7,661.7 | 7,520.1 | 7,122.2 | 7,082.3 | 6,973.5 | 6,703.2 | 6,809.2 |
PBIDT (Excl OI) | 370.0 | 720.0 | 160.0 | 30.0 | 450.0 | 430.0 | -160.0 | -330.0 | 1,114.5 | 958.3 | 1,075.4 | -802.6 | 557.9 | 167.0 | -720.5 | 60.1 |
Other Income | 80.0 | 240.0 | 140.0 | 320.0 | 20.0 | 570.0 | 570.0 | 140.0 | 20.5 | 52.0 | 149.0 | 217.4 | 1,031.3 | 162.4 | 79.5 | 211.7 |
Operating Profit | 450.0 | 960.0 | 300.0 | 350.0 | 470.0 | 1,000.0 | 410.0 | -190.0 | 1,135.0 | 1,010.3 | 1,224.4 | -585.2 | 1,589.2 | 329.4 | -641.0 | 271.8 |
Interest | 770.0 | 760.0 | 790.0 | 760.0 | 830.0 | 700.0 | 730.0 | 860.0 | 800.8 | 690.6 | 641.0 | 546.3 | 598.5 | 609.0 | 737.0 | 614.4 |
Exceptional Items | 0.0 | 0.0 | -140.0 | -960.0 | -30.0 | -1,950.0 | 0.0 | -1,830.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1,424.8 | 0.0 |
PBDT | -320.0 | 200.0 | -630.0 | -1,370.0 | -390.0 | -1,650.0 | -320.0 | -2,880.0 | 334.2 | 319.7 | 583.4 | -1,131.5 | 990.7 | -279.6 | -2,802.8 | -342.6 |
Depreciation | 550.0 | 550.0 | 550.0 | 560.0 | 660.0 | 650.0 | 640.0 | 590.0 | 619.8 | 612.1 | 643.4 | 650.3 | 678.8 | 571.5 | 559.6 | 608.7 |
Profit Before Tax | -870.0 | -350.0 | -1,180.0 | -1,930.0 | -1,050.0 | -2,300.0 | -960.0 | -3,470.0 | -285.6 | -292.4 | -60.0 | -1,781.8 | 311.9 | -851.1 | -3,362.4 | -951.3 |
Tax | -10.0 | 380.0 | 180.0 | 440.0 | -30.0 | -230.0 | -210.0 | -360.0 | -303.3 | -664.1 | 5.8 | -713.4 | -12.1 | -884.0 | -1,106.6 | -1,438.6 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | -860.0 | -730.0 | -1,360.0 | -2,370.0 | -1,020.0 | -2,070.0 | -750.0 | -3,110.0 | 17.7 | 371.7 | -65.8 | -1,068.4 | 324.0 | 32.9 | -2,255.8 | 487.3 |
Net Profit | -860.0 | -730.0 | -1,360.0 | -2,370.0 | -1,020.0 | -2,070.0 | -750.0 | -3,110.0 | 17.7 | 371.7 | -65.8 | -1,068.4 | 324.0 | 32.9 | 7,597.5 | 685.1 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 720.0 | 720.0 | 720.0 | 720.0 | 720.0 | 720.0 | 720.0 | 720.0 | 554.1 | 554.0 | 553.9 | 553.9 | 553.9 | 553.8 | 553.7 | 553.7 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | -5.8 | -5.4 | -9.3 | -14.4 | -6.6 | -13.2 | -4.6 | -21.2 | -0.6 | 3.0 | -1.2 | -8.4 | 1.4 | 0.3 | -20.3 | 2.6 |
Operating Profit Margin | 6.4 | 12.7 | 4.7 | 5.2 | 6.7 | 14.7 | 6.9 | -2.9 | 13.3 | 11.7 | 14.2 | -9.3 | 20.8 | 4.6 | -10.7 | 4.0 |
Net Profit Margin | -12.3 | -9.7 | -21.1 | -35.0 | -14.6 | -30.5 | -12.6 | -47.5 | 0.2 | 4.3 | -0.8 | -16.9 | 4.2 | 0.5 | -37.7 | 7.1 |
The Industry Net Sales Growth stands at 11.00, vs the Net Sales Growth of -20.24, which results in a Negative aspect.
The Industry Mcap Growth stands at 19.42, vs the Mcap Growth of -60.99, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 626.70 | 642.08 | 596.98 |
R3 | 613.03 | 616.45 | 591.34 |
R2 | 599.37 | 601.08 | 589.46 |
R1 | 592.53 | 595.95 | 587.58 |
Pivot | 578.87 | 580.58 | 578.87 |
S1 | 572.03 | 575.45 | 583.82 |
S2 | 558.37 | 560.08 | 581.94 |
S3 | 551.53 | 554.95 | 580.06 |
S4 | 544.70 | 519.08 | 574.43 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
53.16
Neutral
RSI
60.47
Neutral
ROC
-3.05
Bearish
UltimateOscillator
59.76
Neutral
Williams Indicator
-40.83
Neutral
CCI Indicator
11.36
Neutral
MACD
-2,565.41
Bearish
Stochastic Indicator
50.61
Neutral
ATR
30.43
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|
Date Of Conduct | Board Meeting Details |
---|---|
26-03-2024 | Inter alia, to consider and determine the issue price of Equity Shares to be issued pursuant to the Issue, including any discount, not more than 5%, on the floor price calculated in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (?SEBI ICDR Regulations?) and approved by the shareholders of the Company pursuant to a special resolution dated 14th August, 2023. |
14-02-2024 | Quarterly Results |
14-11-2023 | Quarterly Results |
14-08-2023 | Quarterly Results |
26-05-2023 | Audited Results |
13-02-2023 | Quarterly Results |
04-11-2022 | Quarterly Results |
12-08-2022 | Quarterly Results |
30-05-2022 | Audited Results |
03-03-2022 | Rights Issue |
27-01-2022 | Quarterly Results |
06-01-2022 | Inter alia, for considering and approving various fund raising options for the Company, as the Board may deem appropriate |
08-11-2021 | Quarterly Results |
22-07-2021 | Quarterly Results |
27-05-2021 | Audited Results Inter alia, to discuss: raising of funds by issue of Equity Shares, Global Depository Receipts, American depository receipts, Foreign Currency Convertible Bonds, fully convertible debentures, partly convertible debentures, preference shares convertible into Equity Shares, and/or any other financial instruments convertible into Equity Shares (including warrants, or otherwise, in registered or bearer form) and / or any security convertible into equity Shares, combination of any of the aforementioned securities by way of one or more public and/or private offerings, Qualified Institutions Placement and/or on preferential allotment basis or any combination thereof or any other method as may be permitted under applicable law, subject to consent of shareholder at the ensuing Annual General Meeting and such approvals as may be required, and to approve ancillary actions for the above mentioned fund raising |
21-05-2021 | Inter alia, to consider and approve Meeting of the Credit Facilities Committee of the Board of Directors of the Company is scheduled to be held on 21st May, 2021, inter-alia, to consider and approve the proposal for raising of funds through issuance of Non-convertible Debentures on private placement basis. |
21-04-2021 | The meeting of the Credit Facilities Committee of the Board of Directors of the Company is scheduled to be held on 21st April, 2021, inter-alia, to consider and approve the proposal for raising of funds through issuance of Non-Convertible Debentures on private placement basis. |